Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis
This is the first NMA comparing IL-23 inhibitors using contemporary evidence. The results offer practical insights for personalized CD treatment: guselkumab may be preferred for rapid response, mirikizumab for safety, and risankizumab for balanced efficacy.
Authors
- Atsushi Sakuraba (ORCID: https://orcid.org/0000-0003-2519-6129)
- Motoki Kaneko (ORCID: https://orcid.org/0009-0003-3068-8125)
Institutions
- Rush University Medical Center (US)
- Center for Digestive and Liver Diseases (US)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1080/07853890.2025.2595874
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 5.45